Hudson Bay Capital Management LP Makes New $73.08 Million Investment in Edwards Lifesciences Corporation $EW

Hudson Bay Capital Management LP acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 934,449 shares of the medical research company’s stock, valued at approximately $73,083,000. Edwards Lifesciences makes up about 0.2% of Hudson Bay Capital Management LP’s portfolio, making the stock its 28th largest position.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Econ Financial Services Corp bought a new position in Edwards Lifesciences during the second quarter valued at $889,000. Randolph Co Inc bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $301,000. OMERS ADMINISTRATION Corp raised its position in shares of Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Pacific Capital Partners Ltd bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $1,760,000. Finally, Arkadios Wealth Advisors purchased a new position in Edwards Lifesciences in the second quarter worth about $300,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent research reports. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research report on Monday, November 3rd. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Robert W. Baird lifted their price objective on shares of Edwards Lifesciences from $83.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday, December 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $93.30.

Edwards Lifesciences Stock Performance

EW stock opened at $83.06 on Friday. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The firm has a market cap of $48.20 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 3.73 and a beta of 0.97. The business’s fifty day simple moving average is $81.62 and its two-hundred day simple moving average is $79.03. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,465 shares of company stock valued at $3,804,610. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.